Scarica l'app Stockscreener
46.51
0.49%
-0.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
What analysts say about BridgeBio Pharma Inc. stockSky-high return potential - Autocar Professional
What drives BridgeBio Pharma Inc. stock priceOutstanding capital growth - Jammu Links News
Is BridgeBio Pharma Inc. a good long term investmentFree Stock Selection - Jammu Links News
BridgeBio Pharma stock maintains Buy rating at H.C. Wainwright after royalty deal - Investing.com Canada
These 2 Momentum Stocks Got a Bullish Nod — Here’s Why They Could Reach New Highs - The Globe and Mail
Jefferies Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $70 - 富途牛牛
Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
Citi reiterates Buy rating on BridgeBio stock ahead of key trial data - Investing.com Canada
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
BridgeBio Pharma (BBIO) Receives Buy Rating from Jefferies | BBIO Stock News - GuruFocus
Citi Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $67 - 富途牛牛
Jefferies Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma stock initiated with Buy rating at Jefferies on Attruby potential - Investing.com Canada
BridgeBio Pharma's BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 Therapy - AInvest
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights - MSN
Helix shareholders to vote on BridgeBio Oncology merger on August 4 By Investing.com - Investing.com Nigeria
Helix shareholders to vote on BridgeBio Oncology merger on August 4 - Investing.com Australia
Cancer-Focused BridgeBio's $949M SPAC Deal Gets SEC Nod - Law360
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
BridgeBio Pharma stock hits 52-week high, reaching $45.53 By Investing.com - Investing.com South Africa
BridgeBio Pharma Inc. Rockets on Strategic Moves - StocksToTrade
BridgeBio Pharma stock hits 52-week high, reaching $45.53 - Investing.com Australia
Oppenheimer Upgrades BridgeBio Pharma to Outperform From Market Perform, Price Target is $60 - MarketScreener
BridgeBio Pharma (BBIO) Receives Rating Upgrade to Outperform | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Shares Upgraded with Positive Outlook on Future Sales | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Upgraded to Outperform with New Price Target | BBIO Stock News - GuruFocus
BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA - MSN
High Growth Tech Stocks To Watch In The US July 2025 - simplywall.st
BridgeBio Pharma’s SWOT analysis: stock poised for growth on strong pipeline - Investing.com
BridgeBio Pharma (BBIO) Opinions on $300 Million Royalty Financing Deal - Quiver Quantitative
BridgeBio Pharma Enters Royalty Purchase Agreement - TipRanks
Latham & Watkins Advises BridgeBio on US$300 Million Strategic Royalty Sale of BEYONTTRA® European Royalties - Latham & Watkins LLP
Viking Global Investors sells $154 million in BridgeBio Pharma (BBIO) By Investing.com - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Aardvark Therapeutics, Inc. (AARD), BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma director Valantine buys shares worth $30,027 - Investing.com
BridgeBio Pharma Sells Part of Beyonttra Royalty Rights for $300 Million - MarketScreener
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty | BBIO Stock News - GuruFocus
BridgeBio's Strategic Royalty Deal: A Masterclass in Capital Optimization - AInvest
BridgeBio Pharma's Russell Exclusion: A Hidden Growth Catalyst for Biotech Investors? - AInvest
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform’ Rating - MSN
BridgeBio (BBIO) Schedules Investor Webinar on Limb-Girdle Muscu - GuruFocus
BridgeBio (BBIO) Schedules Investor Webinar on Limb-Girdle Muscular Dystrophy | BBIO Stock News - GuruFocus
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET - Yahoo Finance
BridgeBio Pharma (BBIO) Maintains Buy Rating; Price Target Raised | BBIO Stock News - GuruFocus
BridgeBio Pharma (BBIO) Gets a Buy from TD Cowen - The Globe and Mail
Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results - Insider Monkey
10 Biotech Stocks Screaming a Buy - Insider Monkey
Wolfe Research Initiates Coverage on BBIO with Outperform Rating - GuruFocus
Wolfe Research Initiates Coverage on BBIO with Outperform Rating | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Gains Positive Outlook with Strong Transthyreti - GuruFocus
Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target - MarketScreener
BridgeBio (BBIO) Receives Outperform Rating from Wolfe Research | BBIO Stock News - GuruFocus
BridgeBio Pharma stock reaches 52-week high at $40.45 By Investing.com - Investing.com South Africa
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):